Panalgo is now a full-service analytics solutions provider, offering our industry-leading RWE analytics platform, streamlined access to data, and expert analytics services.Panalgo provides software that streamlines healthcare data analytics by removing complex programming from the equation, so customers can focus on what matters most, turning data into actionable insights. The Instant Health Data (IHD) platform empowers teams to turn data into trustworthy results, enabling more impactful decisions. Through partnerships across the industry, we streamline access to real-world data, offering a complete solution from data to insights. Panalgo is a Norstella company, one of the largest global pharma intelligence solution providers. Norstella unites market-leading companies that all have a shared goal of helping bring life-saving therapies to market quicker—from pipeline to patient.

Tempus is a technology company that has built the world's largest, real-world database of molecular and clinical data, and leveraging artificial intelligence (AI) to gather, structure and analyze these data at scale. Tempus generates datasets and analytic tools to support translational research, clinical development, clinical trial recruitment, outcomes research, epidemiology, and commercial analytics. Tempus provides integrated solutions to meet the needs of biopharma and life science companies from early discovery through commercialization--advancing discovery, innovation, and increasing the likelihood of trial success with real-world clinical and molecular data, including DNA, RNA and whole slide pathology images. Through joint research teams combining disciplines from computational biology, medical, bioinformatics, and machine learning, Tempus works alongside your teams with a goal of accelerating therapy development.

As of January 2021, ipm.ai is part of Real Chemistry (previously W2O Group), a global health innovation company leveraging best-in-class, data-driven tech-enabled and digital solutions to deliver clear, concise communications, engagement, activation and value across a full range of healthcare stakeholders – pharma, payors, providers, patients and caretakers.ipm.ai is an Insights as a Service (IaaS) provider that empowers life sciences companies to better understand and improve the lives of patients through the development and commercialization of precision medicine for specialty and rare diseases by utilizing artificial intelligence and machine learning in conjunction with a real-world, patient level claims, affiliations, and social determinants of health (SDOH) data.

ipm.ai is a AI-driven, healthcare predictive analytics firm pioneering the commercial intersection of de-identified patient level data, artificial intelligence (AI) and machine learning (ML) techniques, and precision medicine to better understand, find, and engage ideal patient populations and corresponding HCP treaters. Ultimate goal is to shorten the time to diagnosis, understand the variable patient journeys, identify the right patients/HCPs at the right time, and treat them faster with the right product to improve outcomes. ipm.ai has a keen focus on rare diseases, oncology, and specialty markets to deliver real-time actionable insights to support both clinical and commercial operations. Paid media activation at the NPI level (or consumer) is handled through its parent company, Swoop.com, in collaboration with clients' media advertising agencies.

Insights and Engagement, a business unit within Cardinal Health Specialty Solutions, offers pharmaceutical and biotech manufacturers clinical and commercial expertise, engagement with specialty provider communities, and actionable data-driven solutions to help guide product strategy and marketing execution. Data enriched services include real-world evidence (RWE), strategic consulting, digital marketing, and analytic solutions (+/- GPO members) in the specialty space. In 2019, Cardinal Health was ranked #16 on Fortune 100 with $136.8B total revenue.• Responsible for effectively identifying client needs, developing customized strategic solutions, and converting prospects or new business opportunities into closed deals. • Developed proposals and tactical plans correlated to brand objectives with Brand, Market Access, and Trade teams prior to launch through drug commercialization, leveraging specialty provider networks, advanced analytics, and multi-channel strategies.• Gained distinction in building and closing actionable data driven solutions and new commercial analytic offerings for the business unit.• Structured and negotiated agreements in collaboration with cross-functional teams (i.e., Clinical, Data Science, Commercial Analytics, Engineering, Scientific Communication, Digital Marketing, Market Research, Clinical Operation, etc), Finance, and Legal for optimal execution of data-driven marketing services such as but not limited to HCP education programs, advisory boards, non-personal promotional (NPP) campaigns, chart abstractions, pathway development, and longitudinal, multi-mode research studies.

Cardinal's commercial services and solutions arm, HAMC, focuses on GPO-agnostic strategic consulting, healthcare analytics (including HEOR), digital communications, and medical marketing services for specialty pharmaceutical and biotech industries. Healthcare Analytics and Marketing Communications (HAMC) is a business unit within Specialty Solutions segment of Cardinal Health.Cardinal Health Specialty Solutions (CHSS) brings decades of experience in navigating regulatory pathways, delivering proven channel and distribution solutions, informing product decisions with HEOR and RWE, analyzing data to understand prescriber behavior, and removing barriers to care with proven access and patient support services. Cardinal Health delivers configurable solutions to enhance your product's success on the path to approval, launch, and market adoption.

Harris Interactive was acquired in 2014 by Nielsen, a leading global provider of information and insights. Harris Interactive was a full-service, digital consultative custom market research agency that combines healthcare expertise with award-winning research design. Responsible for business development and client management of quantitative and qualitative market research services for clients across the healthcare industry, including pharmaceuticals, biotech, diagnostics, and medical devices.

Served as the Therapeutic Driver and Risk Evaluation Mitigation Strategy (REMS) Facilitator. Trained, launched, and co-promoted a new FDA indication in Multiple Myeloma. Executed sales and marketing strategies for three pharmaceutical products and a cancer diagnostic tool in a $15M+ territory with teaching institutions, community hospitals, and oncology clinics. Co-promoted and launched an opioid analgesic with Pricara and cancer diagnostic tool with Veridex (both subsidiaries within J&J). Janssen Biotech (formerly Centocor Ortho Biotech), a subsidiary of Johnson & Johnson, specializes in the development and commercialization of therapeutic products for patients that are developed primarily through monoclonal antibody technology.

Managed multi-specialty territory of oncology, nephrology, and surgery specialties at academic institutions and community hospitals. Cultivated and leveraged strong relationships with KOLs, hospital administrators and buyers, and pharmacists to expand the market through execution of core messaging and promotional activities. Served as the VA Team Leader & District Journal Club Leader.

Promoted a blockbuster biologic (PROCRIT) and innovative chemotherapeutic (DOXIL) to hematologists and oncologists in private outpatient clinics and two major Kaiser Permanente hospitals: Harbor City and West LA. Served on the Contracting Advisory Board for the Western Region and as the District’s Reimbursement Specialist.